Incidence and Outcomes of Delayed Targeted Therapy After Cytoreductive Nephrectomy for Metastatic Renal-Cell Carcinoma: A Nationwide Cancer Registry Study

Date
2018
Author
Singla, Nirmish
Freifeld, Yuval
Krabbe, Laura-Maria
Hutchinson, Ryan C.
Lotan, Yair
Hammers, Hans
Hannan, Raquibul
Brugarolas, James
Bagrodia, Aditya
Margulis, Vitaly
Sanli, Oner
Woldu, Solomon L.
Matulay, Justin T.
Clinton, Timothy N.
Metadata
Show full item record
Abstract
The National Cancer Data Base was analyzed to evaluate the impact of delaying initiation of targeted therapy (TT) for metastatic renal-cell carcinoma. After correction for various clinicopathologic factors, delayed initiation of TT was not associated with worse overall survival. This finding supports a practice that appears to be commonplace clinically, although is seldom reported in the literature.
URI
http://hdl.handle.net/20.500.12627/178178
https://doi.org/10.1016/j.clgc.2018.08.001
Collections